GlaxoSmithKline Historical Financial Ratios

GSK Stock  USD 43.50  0.15  0.35%   
GlaxoSmithKline PLC is recently reporting on over 123 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 9.29 or Days Sales Outstanding of 95.02 will help investors to properly organize and evaluate GlaxoSmithKline PLC ADR financial condition quickly.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

About GlaxoSmithKline Financial Ratios Analysis

GlaxoSmithKline PLC ADRFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate GlaxoSmithKline PLC investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on GlaxoSmithKline financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across GlaxoSmithKline PLC history.

GlaxoSmithKline PLC Financial Ratios Chart

GlaxoSmithKline PLC ADR financial ratios usually calculated using numerical values taken directly from GlaxoSmithKline PLC financial statements such as income statements or balance sheets. They help investors to obtain meaningful information about GlaxoSmithKline PLC. Most financial ratios help to conduct quantitative analysis to assess vital information about the company's valuation as well as profitability and liquidity indicators such as leverage, growth, profit margins, and different types of rates of return.
At this time, GlaxoSmithKline PLC's PB Ratio is quite stable compared to the past year. Free Cash Flow Per Share is expected to rise to 1.06 this year, although Book Value Per Share will most likely fall to 2.26.
Add Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity

Price To Sales Ratio

Price to Sales Ratio is figured by comparing GlaxoSmithKline PLC ADR stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on GlaxoSmithKline PLC sales, a figure that is much harder to manipulate than other GlaxoSmithKline PLC ADR multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company’s stock price to its revenues, calculated by dividing the company’s market cap by its total sales or revenue over a 12-month period.

Dividend Yield

Dividend Yield is GlaxoSmithKline PLC ADR dividend as a percentage of GlaxoSmithKline PLC stock price. GlaxoSmithKline PLC ADR dividend yield is a measure of GlaxoSmithKline PLC stock productivity, which can be interpreted as interest rate earned on an GlaxoSmithKline PLC investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.
Most ratios from GlaxoSmithKline PLC's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into GlaxoSmithKline PLC ADR current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
At this time, GlaxoSmithKline PLC's PB Ratio is quite stable compared to the past year. Free Cash Flow Per Share is expected to rise to 1.06 this year, although Book Value Per Share will most likely fall to 2.26.
 2021 2022 2023 2024 (projected)
Dividend Yield0.03820.02950.0190.0181
Price To Sales Ratio3.074.03.893.33

GlaxoSmithKline PLC fundamentals Correlations

-0.770.310.340.39-0.380.3-0.440.090.310.92-0.33-0.140.14-0.26-0.18-0.030.09-0.620.44-0.19-0.310.2-0.19-0.03-0.21
-0.77-0.27-0.4-0.420.06-0.260.17-0.06-0.27-0.650.030.07-0.20.220.25-0.03-0.150.67-0.330.160.48-0.310.170.060.31
0.31-0.270.160.57-0.291.0-0.28-0.171.00.28-0.220.160.020.22-0.010.17-0.040.030.280.09-0.25-0.070.07-0.52-0.24
0.34-0.40.160.01-0.630.15-0.68-0.40.160.06-0.630.43-0.43-0.40.410.79-0.74-0.530.780.64-0.27-0.560.65-0.52-0.32
0.39-0.420.570.01-0.110.57-0.15-0.040.570.42-0.050.170.330.41-0.27-0.090.26-0.10.06-0.12-0.670.21-0.18-0.21-0.6
-0.380.06-0.29-0.63-0.11-0.280.970.4-0.29-0.230.99-0.570.43-0.01-0.42-0.610.640.32-0.89-0.560.270.78-0.540.530.43
0.3-0.261.00.150.57-0.28-0.27-0.171.00.28-0.210.160.020.23-0.010.16-0.040.030.270.08-0.25-0.070.06-0.52-0.24
-0.440.17-0.28-0.68-0.150.97-0.270.45-0.28-0.250.98-0.60.430.03-0.41-0.630.60.4-0.91-0.560.390.71-0.540.550.53
0.09-0.06-0.17-0.4-0.040.4-0.170.45-0.170.150.42-0.290.460.23-0.52-0.620.660.25-0.34-0.730.130.53-0.720.390.21
0.31-0.271.00.160.57-0.291.0-0.28-0.170.28-0.220.160.020.22-0.010.17-0.040.030.280.09-0.25-0.070.07-0.52-0.24
0.92-0.650.280.060.42-0.230.28-0.250.150.28-0.17-0.340.12-0.2-0.13-0.220.22-0.530.16-0.3-0.250.32-0.30.13-0.11
-0.330.03-0.22-0.63-0.050.99-0.210.980.42-0.22-0.17-0.590.450.0-0.43-0.60.630.32-0.88-0.550.280.78-0.530.50.44
-0.140.070.160.430.17-0.570.16-0.6-0.290.16-0.34-0.59-0.160.570.180.56-0.40.230.660.54-0.57-0.680.48-0.59-0.73
0.14-0.20.02-0.430.330.430.020.430.460.020.120.45-0.160.35-0.98-0.690.720.17-0.29-0.71-0.070.65-0.730.43-0.02
-0.260.220.22-0.40.41-0.010.230.030.230.22-0.20.00.570.35-0.3-0.250.360.66-0.04-0.18-0.45-0.07-0.25-0.1-0.5
-0.180.25-0.010.41-0.27-0.42-0.01-0.41-0.52-0.01-0.13-0.430.18-0.98-0.30.71-0.76-0.140.250.770.03-0.670.79-0.45-0.02
-0.03-0.030.170.79-0.09-0.610.16-0.63-0.620.17-0.22-0.60.56-0.69-0.250.71-0.87-0.30.680.91-0.22-0.760.91-0.81-0.33
0.09-0.15-0.04-0.740.260.64-0.040.60.66-0.040.220.63-0.40.720.36-0.76-0.870.28-0.6-0.92-0.020.87-0.940.50.11
-0.620.670.03-0.53-0.10.320.030.40.250.03-0.530.320.230.170.66-0.14-0.30.28-0.42-0.170.20.02-0.20.080.13
0.44-0.330.280.780.06-0.890.27-0.91-0.340.280.16-0.880.66-0.29-0.040.250.68-0.6-0.420.54-0.37-0.690.53-0.59-0.5
-0.190.160.090.64-0.12-0.560.08-0.56-0.730.09-0.3-0.550.54-0.71-0.180.770.91-0.92-0.170.54-0.2-0.831.0-0.6-0.31
-0.310.48-0.25-0.27-0.670.27-0.250.390.13-0.25-0.250.28-0.57-0.07-0.450.03-0.22-0.020.2-0.37-0.20.11-0.130.330.97
0.2-0.31-0.07-0.560.210.78-0.070.710.53-0.070.320.78-0.680.65-0.07-0.67-0.760.870.02-0.69-0.830.11-0.820.540.29
-0.190.170.070.65-0.18-0.540.06-0.54-0.720.07-0.3-0.530.48-0.73-0.250.790.91-0.94-0.20.531.0-0.13-0.82-0.58-0.24
-0.030.06-0.52-0.52-0.210.53-0.520.550.39-0.520.130.5-0.590.43-0.1-0.45-0.810.50.08-0.59-0.60.330.54-0.580.42
-0.210.31-0.24-0.32-0.60.43-0.240.530.21-0.24-0.110.44-0.73-0.02-0.5-0.02-0.330.110.13-0.5-0.310.970.29-0.240.42
Click cells to compare fundamentals

GlaxoSmithKline PLC Account Relationship Matchups

GlaxoSmithKline PLC fundamentals Accounts

201920202021202220232024 (projected)
Price To Sales Ratio4.153.143.074.03.893.33
Ptb Ratio11.77.356.9511.078.859.29
Book Value Per Share3.033.664.72.633.292.26
Free Cash Flow Yield0.04180.05790.0480.04380.03390.039
Operating Cash Flow Per Share2.032.122.481.841.571.58
Pb Ratio11.77.356.9511.078.859.29
Ev To Sales4.923.763.654.594.392.69
Free Cash Flow Per Share1.481.561.571.280.991.06
Net Income Per Share0.781.841.171.441.371.22
Days Of Inventory On Hand182.98186.99181.92196.6221.11153.41
Payables Turnover0.790.740.660.592.442.05
Capex To Revenue(0.0641)(0.0657)(0.0859)(0.077)(0.0773)(0.0812)
Cash Per Share1.211.61.351.961.281.5
Pocfratio17.4812.713.1615.8518.625.66
Interest Coverage7.638.737.917.329.028.57
Pfcf Ratio23.9417.2820.8422.8129.4947.48
Days Payables Outstanding459.64493.98552.2621.31149.48298.06
Income Quality1.521.321.561.51.290.97
Roe(22.53)0.830.390.290.460.42
Ev To Operating Cash Flow20.715.1715.6618.1820.9828.11
Pe Ratio30.1818.6423.8623.8523.9614.42
Return On Tangible Assets0.10.120.140.110.130.21
Ev To Free Cash Flow28.3420.6524.826.1633.2652.2
Earnings Yield0.06150.03310.05360.04190.04170.0812
Intangibles To Total Assets0.520.50.510.360.370.22
Net Debt To E B I T D A2.552.462.261.961.620.85
Current Ratio0.60.750.810.910.791.51
Tangible Book Value Per Share(5.85)(4.93)(6.02)(2.8)(2.17)(2.06)

GlaxoSmithKline PLC Investors Sentiment

The influence of GlaxoSmithKline PLC's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in GlaxoSmithKline. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to GlaxoSmithKline PLC's public news can be used to forecast risks associated with an investment in GlaxoSmithKline. The trend in average sentiment can be used to explain how an investor holding GlaxoSmithKline can time the market purely based on public headlines and social activities around GlaxoSmithKline PLC ADR. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
GlaxoSmithKline PLC's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for GlaxoSmithKline PLC's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average GlaxoSmithKline PLC's news discussions. The higher the estimated score, the more favorable is the investor's outlook on GlaxoSmithKline PLC.

GlaxoSmithKline PLC Implied Volatility

    
  20.17  
GlaxoSmithKline PLC's implied volatility exposes the market's sentiment of GlaxoSmithKline PLC ADR stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if GlaxoSmithKline PLC's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that GlaxoSmithKline PLC stock will not fluctuate a lot when GlaxoSmithKline PLC's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards GlaxoSmithKline PLC in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, GlaxoSmithKline PLC's short interest history, or implied volatility extrapolated from GlaxoSmithKline PLC options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Complementary Tools for GlaxoSmithKline Stock analysis

When running GlaxoSmithKline PLC's price analysis, check to measure GlaxoSmithKline PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline PLC is operating at the current time. Most of GlaxoSmithKline PLC's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline PLC's price. Additionally, you may evaluate how the addition of GlaxoSmithKline PLC to your portfolios can decrease your overall portfolio volatility.
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Fundamental Analysis
View fundamental data based on most recent published financial statements
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Is GlaxoSmithKline PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.30)
Dividend Share
0.59
Earnings Share
2.73
Revenue Per Share
15.15
Quarterly Revenue Growth
0.059
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.